The median survival durations of glioma patients harboring tumors with low and high NFAT5 expression were 19.9 and 9.8 months, respectively (Fig. 1b), and 21.5 and 8.1 months for patients with IDH wild-type GBM, respectively (Fig. 1c). The gene discussed is NFAT5; the disease is central nervous system cancer.